Abstract
While it is well known that Glioblastoma (GBM) shows profound inter- and intra-tumoral heterogeneity, disparities in molecular features across ancestry groups have been largely overlooked. We collected a large cohort of GBM samples from East Asian patients (EAS-GBM) and performed genomic and transcriptomic analyses of these samples (EAS-GBM, n=443). Further characterization and comparative analysis of the EAS-GBM with the predominantly European-ancestry TCGA GBM dataset (EUR-GBM, n=383) revealed differential genomic and genetic landscape and immunological profile of EAS-GBM from EUR-GBM. EAS-GBM showed an enrichment for NF1, H3F3A, TP53 and ATRX mutations compared to EUR-GBM. Transcriptomic clustering revealed distinct EAS-GBM specific subtypes, namely Proliferative (PL), Neuron-Synaptic (NS), Metabolic (MB) and Immunomodulatory (IM). Notably, the classic subtype of EUR-GBMs with EGFR as its main marker gene was absent in EAS-GBMs, Moreover, the IM subgroup in EAS-GBM with an expression profile that has been previously associated with response to immunotherapy in cancers. Together, our comprehensive characterization revealed the unique genomic and genetic features of EAS-GBMs, providing mechanistic rationale in patient stratification for molecular targeted therapy and drug development in the era of personalized medicine.
World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI